This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (81)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

T. S. ZIMMERMAN, MD; J. M. McMILLIN, MD; C. J. WATSON, MD, PhD

Arch Intern Med. 1966;118(3):229-240.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN EARLIER papers^1,2 attention was drawn to the occurrence of cutaneous manifestations of hepatic porphyria after administration of estrogens or estrogen like substances such as chlorotrianisene (Tace); also to the increase of urinary porphobilinogen (PBG) and uroporphyrin in latent hepatic porphyria when diethylstilbestrol was given.³ The latter has also been noted in more extensive studies by Welland and co-workers ⁴ and Redeker.⁵ Of the six cases of cutaneous porphyria in the first report¹ two had been observed by Becker and these have been described by him in more detail.

A number of additional reports have suggested that there are important hormonal influences in hepatic porphyria. These will be discussed in the following. The present objective was to determine the frequency of onset of neurologic or cutaneous manifestations in relation to induced or spontaneous influence of female sex hormones and to consider their effect on porphyrin metabolism and clinical manifestations in . . . [Full Text PDF of this Article]

Author Affiliations
MINNEAPOLIS

From the Department of Medicine, University of Minnesota Hospital, Minneapolis.

Footnotes
Received for publication April 6, 1966; accepted May 23.

Reprint requests to the Department of Medicine, University of Minnesota Medical School, Minneapolis 55455 (Dr. Watson).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?